Nighttime Erections, Vascular Health, and Tadalafil: What the Science Actually Says
A popular social media account post may suggest that longer or stronger nighttime erections are a “tier 1 longevity biomarker” and that daily tadalafil is a longevity medication. The more accurate takeaway is this: erectile function can offer useful information about vascular and metabolic health, but it is not a direct measure of biological age or a guarantee of a longer life.
Tadalafil is an established prescription medication for erectile dysfunction, urinary symptoms from benign prostatic hyperplasia, and pulmonary arterial hypertension in a different formulation. Its possible role in preventing cardiovascular disease or extending lifespan remains unproven.
What are nighttime erections?
Many people with a penis have spontaneous erections during sleep, most commonly during REM sleep. Clinicians call this nocturnal penile tumescence and rigidity, or NPTR. In a medical setting, NPTR testing can measure the number of episodes, changes in circumference, rigidity, and duration over more than one night.
These erections do not require sexual dreams or conscious arousal. They reflect a mix of normal sleep physiology, autonomic nervous-system activity, hormonal status, blood flow, medication effects, alcohol and substance use, mood, and general health.
Nighttime erections are sometimes useful clinically because preserved nocturnal erections can support the possibility that erectile difficulty has a situational, psychological, relationship-related, or medication-related component rather than being entirely vascular. But a home device result—or the absence of remembered morning erections—cannot diagnose cardiovascular disease or determine longevity. Formal NPTR testing has meaningful limitations, including the effects of age, sleep quality, depression, and other confounding factors.[uroweb]
Why erectile function can matter for heart health
Erectile dysfunction shares many risk factors with cardiovascular disease: hypertension, diabetes, dyslipidemia, smoking, obesity, sedentary behavior, obstructive sleep apnea, chronic kidney disease, and vascular disease. Because penile arteries are relatively small, vascular impairment may become clinically apparent there before coronary symptoms develop.
That is why professional urology guidelines recommend treating erectile dysfunction as a potential marker of underlying cardiovascular disease and using it as an opportunity to assess modifiable cardiovascular risk factors.[auanet][auanet]
However, this distinction matters:
Accurate statementOverstatement to avoidPersistent erectile dysfunction can be a reason to review cardiovascular and metabolic risk.A single poor night of erections predicts a heart attack or stroke.Erectile function can change with sleep, stress, medications, alcohol, endocrine status, and vascular health.Erection duration is a validated “longevity score.”Erectile dysfunction is associated with higher cardiovascular risk at a population level.Improving an erection metric has been proven to extend lifespan.A clinician may consider NPTR testing in selected diagnostic situations.Consumer erection-tracking data can replace a cardiovascular evaluation.
The appropriate response to a new, persistent change in erectile function is not panic or an unvalidated tracking protocol. It is a standard health review: blood pressure, lipid profile, glucose or A1c, medication list, sleep quality and possible sleep apnea, tobacco or nicotine exposure, exercise, mental health, and, when appropriate, testosterone and other directed testing.
Is tadalafil a longevity medication?
No. Tadalafil is not FDA-approved for longevity, anti-aging, prevention of heart attack or stroke, dementia prevention, or routine vascular protection in healthy people.
The enthusiasm comes partly from observational data. A large 2024 retrospective analysis of men with erectile dysfunction or lower urinary tract symptoms found that tadalafil and sildenafil use were associated with lower all-cause mortality and lower risks of myocardial infarction, stroke, venous thromboembolism, and dementia over follow-up. In the erectile-dysfunction cohort, the reported relative risk for all-cause mortality was 0.66 for tadalafil and 0.76 for sildenafil.[pubmed.ncbi.nlm.nih][amjmed]
Those findings are interesting—but association is not causation.
People who obtain and continue PDE5-inhibitor therapy may differ from nonusers in important ways that databases cannot fully capture. They may have better access to care, more sexual activity or baseline functional capacity, different comorbidity profiles, higher health engagement, different socioeconomic conditions, or more aggressive treatment of blood pressure, lipids, diabetes, and other risk factors. Even sophisticated statistical adjustment cannot fully eliminate these differences.
To establish tadalafil as a preventive longevity therapy, we would need well-designed randomized trials in appropriately selected populations that measure meaningful outcomes such as cardiovascular events, functional status, adverse effects, and mortality. Those trials are not yet available.
What tadalafil does—and does not do
Tadalafil is a phosphodiesterase type 5 inhibitor, or PDE5 inhibitor. It enhances nitric-oxide/cGMP signaling, which relaxes smooth muscle and increases blood flow in certain tissues. This is why it can improve erectile function and urinary symptoms for appropriate patients.
A daily 2.5 mg or 5 mg regimen is an approved option for some people being treated for erectile dysfunction, based on the clinical indication, patient preference, and prescriber judgment—not because it has been proven to prevent aging.[uroweb]
Potential benefits for an appropriate patient may include:
Improved ability to achieve or maintain erections with sexual stimulation
Improved lower urinary tract symptoms for some patients with benign prostatic hyperplasia
Greater sexual confidence and quality of life when erectile dysfunction is contributing to distress
Treatment of certain approved cardiopulmonary conditions in specialized dosing and care settings
Potential adverse effects include headache, flushing, nasal congestion, indigestion or reflux, back pain, muscle aches, dizziness, and blood-pressure lowering. Rare but urgent complications include priapism, sudden hearing change, and sudden visual symptoms.
Most importantly, tadalafil must not be combined with nitrates, including nitroglycerin, because the combination can cause a dangerous drop in blood pressure. It is also contraindicated with guanylate-cyclase stimulators such as riociguat. The prescribing information advises avoiding nitrates for at least 48 hours after the last tadalafil dose.[dailymed.nlm.nih][dailymed.nlm.nih]
People considering tadalafil should also review alpha-blockers, antihypertensives, significant heart disease, recent cardiovascular events, kidney or liver impairment, and drug interactions with a clinician or pharmacist.
What about women and nighttime genital arousal?
Women can experience sleep-related genital vasocongestion, including clitoral engorgement and vaginal blood-flow changes. In research settings, genital response can be measured with specialized tools such as vaginal or clitoral photoplethysmography, which detects changes in genital blood volume or pulse amplitude.[pmc.ncbi.nlm.nih][pubmed.ncbi.nlm.nih]
But there is no broadly validated, consumer-ready “female nighttime arousal” tracker that functions as a cardiovascular-risk or longevity monitor. Claims that female nighttime genital arousal can be routinely tracked and interpreted like a wearable cardiovascular metric go far beyond current clinical practice.
More broadly, sexual function in women is influenced by vascular health, hormones, pelvic-floor function, medications, mood, relationship context, pain, sleep, trauma history, and many other factors. A reduction in genital arousal or lubrication is not, by itself, a validated proxy for cardiovascular disease or lifespan.
A practical, evidence-based approach
Sexual function belongs in preventive medicine—but it should be treated as one part of the overall picture, not as a biological-age contest.
If someone notices a persistent change in erections, libido, arousal, lubrication, orgasm, or genital pain, a helpful next step is a medical evaluation that includes:
Blood pressure and cardiovascular-risk assessment
Screening for diabetes or insulin resistance when indicated
Lipid testing and review of smoking, vaping, alcohol, and substance use
Medication review, including antidepressants, antihypertensives, opioids, and hormonal therapies
Assessment for sleep disruption or obstructive sleep apnea
Discussion of stress, depression, anxiety, relationship factors, and pelvic health
Targeted hormone testing only when the history and examination support it
The interventions with the clearest evidence for long-term cardiovascular health remain comparatively unglamorous: regular physical activity, resistance training, adequate sleep, smoking cessation, blood-pressure control, diabetes prevention or treatment, lipid management when indicated, nutritious dietary patterns, and appropriate treatment of sleep apnea.
Bottom line
Nighttime erections are a normal physiologic phenomenon, and erectile dysfunction can be an important signal to assess cardiovascular and metabolic health. That makes sexual health clinically meaningful—not a validated standalone measure of longevity.
Tadalafil is a valuable medication when appropriately prescribed. Observational studies suggesting cardiovascular and mortality associations are promising, but they do not establish that taking tadalafil prevents disease or prolongs life in otherwise healthy people. Decisions about daily tadalafil should be individualized, indication-based, and made with attention to cardiovascular history, concurrent medications, and safety—not driven by social-media claims.
